PDX Pharma’s ARAC-02 drug candidate has been selected into the Nanotechnology Characterization Lab (NCL)’s collaboration and characterization program.

The Nanotechnology Characterization Laboratory (NCL) was founded in 2004 by the National Cancer Institute (NCI) in collaboration with the US Food and Drug Administration (FDA) and National Institute of Standards and Technology (NIST). The NCL’s mission is to accelerate the translation of promising nanotech cancer drugs and diagnostics. PDX Pharma’s proprietary platform (Pdx-NP™) utilizes polymer-modified mesoporous silica nanoparticles and can effectively co-deliver a plethora of therapeutic modalities while maintaining a small size, suitable for infusion and tumor accumulation. ARAC-02, one of our leading candidates, targets PD-L1, PLK1, and TLR9, and has the ability to simultaneously kill cancer while also inducing a potent anti-tumor immune response. ARAC-02 development won a $2.3M fast track SBIR award from the NCI with a rare perfect score in September 2021. In December 2022, ARAC-02 was selected into the NCL’s Assay Cascade Characterization Program, during which its physicochemical properties and in vitro and in vivo compatibility (immunology, pharmacology, and toxicology) will be characterized at no cost using a standardized assay cascade developed in collaboration with the FDA and NIST. This program will directly support our IND enabling studies toward the clinical adoption of ARAC-02.  

To read more, click here